Precision Medicine in Oncology® | Specialty

Dr. Shunyakov on the Impact of Genomics on Personalized Therapy in Oncology

July 27th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses how genomics have impacted personalized therapy in oncology.

Immunotherapy Requires Precision Medicine Approach for NSCLC

July 27th 2018

Immunotherapy should be given as a tailored, not blanket, treatment approach, especially for patients with lung cancer, according to Giorgio Scagliotti, MD, PhD.

Targeted Therapy Options Expanding for NSCLC

July 27th 2018

Several novel targeted therapies are emerging for a growing number of driver mutations in lung cancer, with multiple targeted agents now confirmed standards of care.

Dr. Shunyakov on the Impact of Next-Generation Sequencing in Oncology

July 20th 2018

Leonid Shunyakov, MD, hematologist/oncologist, Central Care Cancer Center, discusses the impact of next-generation sequencing (NGS) in oncology.

Defining Precision Cancer Medicine the Right Way

July 17th 2018

Maurie Markman, MD, defines precision medicine in oncology.

NTRK Gene Fusions: Novel Targets for Tumor-Agnostic Cancer Therapy

June 20th 2018

Advanced sequencing techniques have revolutionized the understanding of how cancer has developed and enabled treatment selection based on genomic characterization of the tumor.

Novel Targeted Antibody-Drug Conjugates in Non-Hodgkin Lymphoma

June 18th 2018

Antibody-drug conjugates represent a targeted class of agents with an improved therapeutic index over traditional chemotherapy in the treatment of non-Hodgkin lymphoma.

BET Inhibitors Form a Growing Area of Epigenetic Cancer Research

June 14th 2018

Rapid progress in the development of BET inhibitors has created a surge of enthusiasm.

The Continuum of Care in NSCLC

May 25th 2018

NSCLC Patients and Education About Therapy

May 25th 2018

Communicating With the NSCLC Patient

May 25th 2018

Precision Medicine for NSCLC and the Role of APPs

May 25th 2018

Importance of Tumor Boards in NSCLC Management

May 25th 2018

How Much Tissue Do You Need for NSCLC Diagnosis?

May 25th 2018

Pathologist Role in Tissue Acquisition for NSCLC Diagnosis

May 25th 2018

Optimal Multidisciplinary Teamwork in NSCLC

May 25th 2018

Patient Shortage for Cancer Trials Grows

April 30th 2018

Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

Frontline Osimertinib Approaches European Approval for NSCLC

April 27th 2018

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.

Managing Ovarian Cancer Patients in the Future

April 26th 2018

Therapy Selection in BRCA-Mutated Ovarian Cancer

April 26th 2018